1. Home
  2. BLRX vs JCTC Comparison

BLRX vs JCTC Comparison

Compare BLRX & JCTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • JCTC
  • Stock Information
  • Founded
  • BLRX 2003
  • JCTC 1953
  • Country
  • BLRX Israel
  • JCTC United States
  • Employees
  • BLRX N/A
  • JCTC N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • JCTC
  • Sector
  • BLRX Health Care
  • JCTC
  • Exchange
  • BLRX Nasdaq
  • JCTC NYSE
  • Market Cap
  • BLRX 17.3M
  • JCTC 15.9M
  • IPO Year
  • BLRX 2011
  • JCTC 1996
  • Fundamental
  • Price
  • BLRX $3.59
  • JCTC $4.87
  • Analyst Decision
  • BLRX Strong Buy
  • JCTC
  • Analyst Count
  • BLRX 2
  • JCTC 0
  • Target Price
  • BLRX $220.00
  • JCTC N/A
  • AVG Volume (30 Days)
  • BLRX 154.8K
  • JCTC 8.7K
  • Earning Date
  • BLRX 03-25-2025
  • JCTC 04-14-2025
  • Dividend Yield
  • BLRX N/A
  • JCTC N/A
  • EPS Growth
  • BLRX N/A
  • JCTC N/A
  • EPS
  • BLRX N/A
  • JCTC N/A
  • Revenue
  • BLRX $21,991,000.00
  • JCTC $46,606,336.00
  • Revenue This Year
  • BLRX N/A
  • JCTC N/A
  • Revenue Next Year
  • BLRX N/A
  • JCTC N/A
  • P/E Ratio
  • BLRX N/A
  • JCTC N/A
  • Revenue Growth
  • BLRX N/A
  • JCTC N/A
  • 52 Week Low
  • BLRX $3.20
  • JCTC $3.86
  • 52 Week High
  • BLRX $57.60
  • JCTC $5.71
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 36.94
  • JCTC N/A
  • Support Level
  • BLRX $3.26
  • JCTC N/A
  • Resistance Level
  • BLRX $4.17
  • JCTC N/A
  • Average True Range (ATR)
  • BLRX 0.28
  • JCTC 0.00
  • MACD
  • BLRX 0.24
  • JCTC 0.00
  • Stochastic Oscillator
  • BLRX 36.26
  • JCTC 0.00

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About JCTC JEWETT-CAMERON TRADING CO

Jewett-Cameron Trading Co Ltd through its subsidiaries engages in the wholesale distribution of a variety of specialty wood products. Its operating segments include, The Industrial wood products segment is engaged in the processing and distribution of industrial wood products. The Pet Fencing and Other segment, which is the key revenue driver, operates as a wholesaler of wood products and a manufacturer and distributor of specialty metal products. The Seed processing and sales segment processes and distributes agricultural seed and Corporate and administrative. The company predominantly operates in the United States and also has a presence in Canada, Latin America, Europe and Asia Pacific, and other regions.

Share on Social Networks: